| People | Locations | Statistics |
|---|---|---|
| Naji, M. |
| |
| Motta, Antonella |
| |
| Aletan, Dirar |
| |
| Mohamed, Tarek |
| |
| Ertürk, Emre |
| |
| Taccardi, Nicola |
| |
| Kononenko, Denys |
| |
| Petrov, R. H. | Madrid |
|
| Alshaaer, Mazen | Brussels |
|
| Bih, L. |
| |
| Casati, R. |
| |
| Muller, Hermance |
| |
| Kočí, Jan | Prague |
|
| Šuljagić, Marija |
| |
| Kalteremidou, Kalliopi-Artemi | Brussels |
|
| Azam, Siraj |
| |
| Ospanova, Alyiya |
| |
| Blanpain, Bart |
| |
| Ali, M. A. |
| |
| Popa, V. |
| |
| Rančić, M. |
| |
| Ollier, Nadège |
| |
| Azevedo, Nuno Monteiro |
| |
| Landes, Michael |
| |
| Rignanese, Gian-Marco |
|
Mcconville, Christopher
University of Birmingham
in Cooperation with on an Cooperation-Score of 37%
Topics
Publications (11/11 displayed)
- 2022ChemoSeed®: A Novel Implantable Device for the Treatment of High Grade Gliomas
- 2021Development and Optimization of Irinotecan-Loaded PCL Nanoparticles and Their Cytotoxicity against Primary High-Grade Glioma Cells.citations
- 2021Continuous manufacture of hydroxychloroquine sulfate drug products via hot melt extrusion technology to meet increased demand during a global pandemic: From bench to pilot scalecitations
- 2021Continuous manufacture of hydroxychloroquine sulfate drug products via hot melt extrusion technology to meet increased demand during a global pandemic: From bench to pilot scalecitations
- 2020Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme.citations
- 2019Comparison of fused-filament fabrication to direct compression and injection molding in the manufacture of oral tabletscitations
- 2018Material considerations for fused-filament fabrication of solid dosage forms.citations
- 2018Material considerations for fused-filament fabrication of solid dosage formscitations
- 2016A Synthetic Route for the Effective Preparation of Metal Alloy Nanoparticles and Their Use as Active Electrocatalystscitations
- 2015Hot melt extruded and injection moulded dosage formscitations
- 2012Development of polylactide and polyethylene vinyl acetate blends for the manufacture of vaginal rings.citations
Places of action
| Organizations | Location | People |
|---|
article
ChemoSeed®: A Novel Implantable Device for the Treatment of High Grade Gliomas
Abstract
<jats:title>Abstract</jats:title><jats:sec><jats:title>AIMS</jats:title><jats:p>The treatment of high grade gliomas (HGGs) is extremely toxic, while offering a dismal prognosis of 15 months survival. Irinotecan (IRN) is a second-line therapy due to its dose-limiting toxicities when delivered systemically. The aim of this research is to formulate IRN into ChemoSeed for local administration to the resection margin of HGGs and evaluate it for toxicity and efficacy in a Patient-Derived Xenograft mouse resection model.</jats:p></jats:sec><jats:sec><jats:title>METHOD</jats:title><jats:p>30 and 40% w/w IRN-loaded ChemoSeeds were manufactured using hot melt extrusion and were subsequently implanted into the resection cavity of HGG tumour bearing mice.</jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p>The 30% w/w IRN-loaded ChemoSeeds showed moderate local toxicity two days after implantation, which diminished by day 4. The 40% w/w IRN-loaded ChemoSeeds showed signs of moderate local toxicity up to six days post implantation, diminishing by day 8 with mild toxicity returning at day 14. Histopathology of the implantation site showed signs of the onset of necrosis at day 45 and 14 for the 30% and 40% w/w IRN-loaded ChemoSeeds. Hematological analysis and clinical chemistry showed no signs of serious systemic toxicity for either the 30 or 40% w/w IRN-loaded ChemoSeeds. The 30% w/w IRN-loaded ChemoSeeds had an 80% survival at day 148, with no sign of tumour recurrence, while the 40% w/w group showed signs of tumour recurrence at day 21, with all mice dead by day 70.</jats:p></jats:sec><jats:sec><jats:title>CONCLUSION</jats:title><jats:p>This study demonstrates that the 30% w/w IRN-loaded ChemoSeeds are a promising novel treatment for HGGs that could be quickly translated into the clinic.</jats:p></jats:sec>